TrialSite recently suggested based on unfolding study results that repurposed IL-6 inhibitors, such as Roche’s Actemra®/ReActemtra® (tocilizumab), may not work to treat patients infected with COVID-19. TrialSite pointed to the results of an Italian study as a...
Immunosuppressive
Category
Revlmmune Initiates Phase 2 Trial of T-Cell Growth Factor Called CYT107 for COVID-19
Although many COVID-19 clinical trials have focused on decreasing the hyper-inflammatory phase that often occurs in patients and can cause substantial damage, there is a growing recognition that this phase is generally temporary. Often this is followed by a stage of...
Samsung Bioepis HUMIRA Biosimilar Approved in the U.S. & Will be Available in June 2023 Due to Patent Thicket
Samsung Bioepis Co. Ltd. reports that the U.S. FDA has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult...
Biologics Associated with 34,000 Deaths Since 2004: What Are the Implications?
Costly Biologics to treat diseases such as autoimmune diseases have flooded the market over the past couple of decades. Prominently advertised on television ads promising improved gastrointestinal symptoms or clearer skin with “sexy elbows.” They are effective for...